{"id":14568,"date":"2012-02-09T08:30:00","date_gmt":"2012-02-09T07:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/sanofi-riceve-270-mln-da-plavix\/"},"modified":"2012-02-09T08:30:00","modified_gmt":"2012-02-09T07:30:00","slug":"sanofi-riceve-270-mln-da-plavix","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/sanofi-riceve-270-mln-da-plavix\/","title":{"rendered":"Sanofi receives 270 mln $ from Plavix"},"content":{"rendered":"<p style=\"line-height: 125%; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"line-height: 125%; font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-bidi-font-family: Arial; mso-ansi-language: EN\" lang=\"EN\">Last updated:February 8, 2012 8:15 pm<\/p>\n<p><\/span><\/p>\n<p style=\"line-height: 125%; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"line-height: 125%; font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-bidi-font-family: Arial; mso-ansi-language: EN\" lang=\"EN\">By Andrew Jack in London&nbsp;&nbsp;&nbsp; <img loading=\"lazy\" decoding=\"async\" style=\"width: 126px; height: 94px\" id=\"rg_hi\" class=\"rg_hi\" alt=\"\" width=\"274\" height=\"184\" data-width=\"274\" data-height=\"184\" src=\"http:\/\/t0.gstatic.com\/images?q=tbn:ANd9GcRgPXe8Z1HTO09kMD-ZK6BrGHUPYRbJ4NGvGiV-y3xgN09KCEOu4Q\" \/><\/span><\/p>\n<p style=\"line-height: 125%; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\" align=\"right\"><span style=\"line-height: 125%; font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-bidi-font-family: Arial; mso-ansi-language: EN\" lang=\"EN\"><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" style=\"padding-bottom: 8px; width: 342px; padding-right: 8px; height: 178px; padding-top: 8px\" id=\"il_fi\" alt=\"\" width=\"507\" height=\"343\" src=\"http:\/\/www.pulaskilawfirm.com\/wp-content\/uploads\/2011\/12\/Plavix.jpg\" \/><\/p>\n<p><\/span><\/p>\n<p style=\"line-height: 125%; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"line-height: 125%; font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-bidi-font-family: Arial; mso-ansi-language: EN\" lang=\"EN\"><a href=\"http:\/\/markets.ft.com\/tearsheets\/performance.asp?s=fr:SAN\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #2e6e9e; text-decoration: none; text-underline: none\">Sanofi<\/span><\/a>, the French pharmaceutical group, will receive a $270m payment from its generic rival Apotex over rights to its blockbuster blood thinner Plavix, briefly easing the impact of patent expiries on one of the world&rsquo;s top-selling drugs.<\/p>\n<p><\/span><\/p>\n<p style=\"line-height: 125%; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"line-height: 125%; font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-bidi-font-family: Arial; mso-ansi-language: EN\" lang=\"EN\">The settlement &ndash; bringing to an end a decade-old legal dispute &ndash; came as Sanofi <a title=\"Sanofi 2011 results\" href=\"http:\/\/en.sanofi.com\/Images\/29618_20120208_2011_Results_EN.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #2e6e9e; text-decoration: none; text-underline: none\">posted 2011 pre-tax profits <\/span><\/a>ahead of joint ventures down 14 per cent to &euro;5.3bn on sales up 3 per cent to &euro;33.4bn. Sanofi warned that loss of exclusivity on Plavix and Avapro would this year help depress earnings by a further 12-15 per cent.<\/p>\n<p><\/span><\/p>\n<p style=\"line-height: 125%; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"line-height: 125%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-ansi-language: EN\" lang=\"EN\">Plavix, which is set to be the world&rsquo;s top-selling drug following the patent expiries on Pfizer&#038;rsq<\/p>","protected":false},"excerpt":{"rendered":"<p>Last updated:February 8, 2012 8:15 pm By Andrew Jack in London&nbsp;&nbsp;&nbsp; Sanofi, the French pharmaceutical group, will receive a $270m payment from its generic rival Apotex over rights to its blockbuster blood thinner Plavix, briefly easing the impact of patent expiries on one of the world&rsquo;s top-selling drugs. The settlement &ndash; bringing to an end &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14568"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}